Analyst: Biogen Idec Gains Are Done
ThinkstockBiogen Idec Inc. (NASDAQ: BIIB) has had a great 2012. Actually, it has had a hell of a year with a gain of almost 40% year to date. When you compare this to the…
ThinkstockBiogen Idec Inc. (NASDAQ: BIIB) has had a great 2012. Actually, it has had a hell of a year with a gain of almost 40% year to date. When you compare this to the…
ThinkstockWe have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Biogen Idec…
We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Biogen Idec…
The short interest in biotech stocks is mixed, judging by the short interest changes between the September 14 and September 28 settlement dates. There were notable swings in shares sold short from…
With a couple of exceptions, the short interest in biotech stocks is on the rise again, judging by the short interest changes from September 14 settlement date versus the August 31 settlement…
The short interest in biotech stocks is generally falling, judging by the short interest changes from August 31 settlement date versus the August 15 settlement date. We have tracked the key short…
Index changes are generally speaking a fairly routine event. They can also create underlying moves in the companies added and deleted from them as money management firms often buy and sell shares,…
Thursday brought yet more merger and acquisition news in the ongoing buyout trends in the biotech sector. Amgen Inc. (NASDAQ: AMGN) announced that it is going to acquire Micromet, Inc. (NASDAQ: MITI), a…
Dendreon Corporation (NASDAQ: DNDN) is living up to something we showed late in December. It was one of the Top Biotech Upside Stocks for 2012 by Wall Street Analysts. Now, the question…
The biotech sector has seen its share of ups and downs in 2011 and prior years. It is almost always the case that some of the top performing stocks each year come…
We have compiled a detailed list of expected upside in the biotech sector. The sector has consolidated and now there is about to be a rush of earnings reports from tomorrow’s emerging…
Biotech is becoming the ever-shrinking stock sector. It is almost weekly now that a new biotech acquisition is announced. Big Pharma in the United States and large drugmakers internationally are all interested in acquiring the…
The proposed buyout of Genzyme Corporation (NASDAQ: GENZ) by Sanofi-Aventis (NYSE: SNY) should close this week. We are about to get a new Genzyme security on the market and that will be…
Futurists are an odd lot. Generally, they are authors, scientists, consultants and economists. What many people don’t know is that investors follow this philosophy as well. Their goal is to pick winning…
Today’s version of the BioHealth Business Daily is rather different as we have a big disappointment from one of the top biotech operations in the world. BioHealth stocks moving on news and…